Drug Profile
Research programme: bromodomain inhibitors - 4SC Discovery/CRELUX
Alternative Names: Cancer therapeutics - 4SC Discovery/CRELUX; Epigenetic-modulator inhibitors - 4SC Discovery/CRELUXLatest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator 4SC Discovery; CRELUX
- Class Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Cancer in Germany
- 15 Apr 2016 CRELUX has been acquired by WuXi AppTec
- 24 Jul 2014 Early research in Cancer in Germany (unspecified route)